Inhalation Sciences receives new order worth 360,000 SEK from long-term global pharma client
(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required software update work from a long-term client, a leading global pharmaceutical company.
The client has an extensive generics pipeline and robust R&D organisation. It has ISAB’s high-precision aerosol generation system PreciseInhale® installed in-house, as well as its in vitro lung simulation module DissolvIt®. Prior to purchase and installation, the client carried out a series of successful clinical research projects with Inhalation Research Services - ISAB’s contract research team. The current purchase order is for development work and required software upgrades.
ISAB CEO Manoush Masarrat: “We are pleased to continue this long and much-valued relationship. Our technology has proved itself every step of the way for our client. Now our development and software service work will ensure that this excellent performance continues.”
Read more about PreciseInhale® here
PreciseInhale® is ISAB’s aerosol generation system that enables precision dosing across a range of in vitro and in vivo exposure modules. PreciseInhale® has now also been validated for clinical use.
Read more about DissolvIt® here
DissolvIt® is ISAB’s leading in vitro lung dissolution module, delivering high-precision, predictive in vitro in vivo correlated (IVIVC) data. The US FDA has now approved ISAB’s proposal for a research study aiming to validate DissolvIt® as an FDA-recommended technology, and will support and co-finance the study.
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, whether new pollutants or life-saving drugs that power human development.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 5, 2022.
Tags: